Francesca Carlomagno
Francesca Carlomagno
Professore di Patologia Generale, Universita' degli Studi di Napoli Federico II
No verified email
TitleCited byYear
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
M Santoro, F Carlomagno, A Romano, DP Bottaro, NA Dathan, M Grieco, ...
Science 267 (5196), 381-383, 1995
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno, S Anaganti, T Guida, G Salvatore, G Troncone, ...
Journal of the National Cancer Institute 98 (5), 326-334, 2006
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
M Santoro, F Carlomagno, ID Hay, MA Herrmann, M Grieco, R Melillo, ...
The Journal of clinical investigation 89 (5), 1517-1522, 1992
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor …
F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ...
Clinical Cancer Research 9 (4), 1546-1556, 2003
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
G Tallini, M Santoro, M Helie, F Carlomagno, G Salvatore, G Chiappetta, ...
Clinical Cancer Research 4 (2), 287-294, 1998
The extent of linkage disequilibrium in four populations with distinct demographic histories
AM Dunning, F Durocher, CS Healey, MD Teare, SE McBride, ...
The American Journal of Human Genetics 67 (6), 1544-1554, 2000
New therapeutic approaches to treat medullary thyroid carcinoma
M Schlumberger, F Carlomagno, E Baudin, JM Bidart, M Santoro
Nature Reviews Endocrinology 4 (1), 22, 2008
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno, T Guida, S Anaganti, G Vecchio, A Fusco, AJ Ryan, ...
Oncogene 23 (36), 6056, 2004
Minireview: RET: normal and abnormal functions
M Santoro, RM Melillo, F Carlomagno, G Vecchio, A Fusco
Endocrinology 145 (12), 5448-5451, 2004
Molecular mechanisms of RET activation in human cancer
M Santoro, RM Melillo, F Carlomagno, A Fusco, G Vecchio
Annals of the New York Academy of Sciences 963 (1), 116-121, 2002
BRAF is a therapeutic target in aggressive thyroid carcinoma
G Salvatore, V De Falco, P Salerno, TC Nappi, S Pepe, G Troncone, ...
Clinical Cancer Research 12 (5), 1623-1629, 2006
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas
MD Castellone, V Guarino, V De Falco, F Carlomagno, F Basolo, ...
Oncogene 23 (35), 5958, 2004
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes
F Carlomagno, D Vitagliano, T Guida, M Napolitano, G Vecchio, A Fusco, ...
Cancer Research 62 (4), 1077-1082, 2002
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways …
M Chiariello, R Visconti, F Carlomagno, RM Melillo, C Bucci, ...
Oncogene 16 (19), 2435, 1998
Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
F Carlomagno, G De Vita, MT Berlingieri, V De Franciscis, RM Melillo, ...
The EMBO Journal 15 (11), 2717-2725, 1996
Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2)
F Carlomagno, D Vitagliano, T Guida, F Basolo, MD Castellone, ...
The Journal of Clinical Endocrinology & Metabolism 88 (4), 1897-1902, 2003
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma
F Basolo, R Giannini, C Monaco, RM Melillo, F Carlomagno, M Pancrazi, ...
The American journal of pathology 160 (1), 247-254, 2002
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype
F Carlomagno, G Salvatore, AM Cirafici, G De Vita, RM Melillo, ...
Cancer Research 57 (3), 391-395, 1997
Dysfunction of the RET receptor in human cancer.
M Santoro, F Carlomagno, RM Melillo, A Fusco
Cellular and molecular life sciences: CMLS 61 (23), 2954-2964, 2004
The system can't perform the operation now. Try again later.
Articles 1–20